Julio Chavez

43PUBLICATIONS
246CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Biologically active moleculesEpigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Jul 08, 2026
Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

|Jun 12, 2026
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

|Jun 03, 2026
Managing cytokine release syndrome in hematological malignancies being treated with CAR-T cell therapy.

|May 19, 2026
From immunomodulators (IMiDs) to cereblon E3 ligase modulator (CELMoDs): the evolution of cereblon modulators in lymphoma therapy.

|May 15, 2026
Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management.

|Apr 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Pageof 8

Frequent Collaborators

7 joint publications

Michael Jain

5 joint publications

Jorge J Castillo

4 joint publications

Olalekan Oluwole

4 joint publications

Frederick L Locke